These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 37950281)
1. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer. Wang T; Wang D; Sun Y; Zhuang T; Li X; Yang H; Zang Y; Liu Z; Yang P; Zhang C; Cui J; Fu M; Zhang S; Su P; Li Z; Zhu J; Ding Y J Exp Clin Cancer Res; 2023 Nov; 42(1):297. PubMed ID: 37950281 [TBL] [Abstract][Full Text] [Related]
2. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway. Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277 [TBL] [Abstract][Full Text] [Related]
3. PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis. Xu W; Yang Z; Xie C; Zhu Y; Shu X; Zhang Z; Li N; Chai N; Zhang S; Wu K; Nie Y; Lu N J Exp Clin Cancer Res; 2018 Aug; 37(1):198. PubMed ID: 30134988 [TBL] [Abstract][Full Text] [Related]
4. OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer. Yan C; Yang H; Su P; Li X; Li Z; Wang D; Zang Y; Wang T; Liu Z; Bao Z; Dong S; Zhuang T; Zhu J; Ding Y Oncogene; 2022 Nov; 41(48):5186-5198. PubMed ID: 36271031 [TBL] [Abstract][Full Text] [Related]
5. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway. Li T; Guo T; Liu H; Jiang H; Wang Y Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116 [TBL] [Abstract][Full Text] [Related]
6. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion. Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076 [TBL] [Abstract][Full Text] [Related]
7. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762 [TBL] [Abstract][Full Text] [Related]
8. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Dong L; Lin F; Wu W; Liu Y; Huang W Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256 [TBL] [Abstract][Full Text] [Related]
9. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer. Wang D; Li Z; Li X; Yan C; Yang H; Zhuang T; Wang X; Zang Y; Liu Z; Wang T; Jiang R; Su P; Zhu J; Ding Y J Exp Clin Cancer Res; 2022 Jul; 41(1):219. PubMed ID: 35820928 [TBL] [Abstract][Full Text] [Related]
10. EP300 promotes lung cancer cell proliferation by regulating the oncogenic transcription of Hippo-YAP signaling pathway. Li S; Shi J; Wang L; Zhang D; Zhang H Biochem Biophys Res Commun; 2024 Jan; 692():149330. PubMed ID: 38048728 [TBL] [Abstract][Full Text] [Related]
11. MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway. An L; Nie P; Chen M; Tang Y; Zhang H; Guan J; Cao Z; Hou C; Wang W; Zhao Y; Xu H; Jiao S; Zhou Z J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32271880 [TBL] [Abstract][Full Text] [Related]
12. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2. Zhou X; Li Y; Wang W; Wang S; Hou J; Zhang A; Lv B; Gao C; Yan Z; Pang D; Lu K; Ahmad NH; Wang L; Zhu J; Zhang L; Zhuang T; Li X Theranostics; 2020; 10(21):9443-9457. PubMed ID: 32863938 [No Abstract] [Full Text] [Related]
13. The Hippo signaling pathway in gastric cancer. Cao Z; An L; Han Y; Jiao S; Zhou Z Acta Biochim Biophys Sin (Shanghai); 2023 Mar; 55(6):893-903. PubMed ID: 36924251 [TBL] [Abstract][Full Text] [Related]
14. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099 [TBL] [Abstract][Full Text] [Related]
16. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling. Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216 [TBL] [Abstract][Full Text] [Related]
17. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645 [TBL] [Abstract][Full Text] [Related]
18. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway. Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643 [TBL] [Abstract][Full Text] [Related]
19. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Sun Y; Jiang T; Jia Y; Zou J; Wang X; Gu W Cell Cycle; 2019 Oct; 18(19):2509-2523. PubMed ID: 31397203 [TBL] [Abstract][Full Text] [Related]
20. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway. Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]